In the Media

MIT Innovation Fellow Brian Deese speaks with CNBC about how the new class of weight loss drugs will impact American taxes and the federal deficit. “These drugs could touch tens of millions of Americans, that’s the good news,” says Deese. “They have the potential to reduce obesity, address diabetes and reduce the health care costs associated with that. The problem is that the scale and the cost of these drugs is so large, that it could add enormously to the federal budget.”